Shares of clinical-stage biotech Pliant Therapeutics (NASDAQ: PLRX) were up more than 14% as of 11 a.m. ET on Tuesday after the company announced positive phase 2a trial information for its lead therapy. The stock is down more than 12% so far this year.
Pliant focuses on therapies to treat fibrotic conditions. On Tuesday, before the markets opened, the healthcare company said that its therapy bexotegrast met its primary and secondary endpoints after 12 weeks to treat the respiratory disease idiopathic pulmonary fibrosis (IPF) and the liver ailment primary sclerosing cholangitis (PSC). Pliant said the therapy was well tolerated and reduced the enhanced liver fibrosis (ELF) score and collagen synthesis biomarker levels compared to a placebo.
The company also said that the therapy helped stabilize patient liver chemistry, compared to a placebo, along with improved hepatocyte function and bile flow.
Pliant said the results give it confidence to continue trials and to also look at other pulmonary and liver indications for the drug.
Pliant offers plenty of potential along with the obvious risk for any clinical-stage biotech. Bexotegrast’s target market is quite large. The American Liver Foundation estimates that more than 100 million people in the U.S. have some form of liver disease, and the the drug has already received an Orphan Drug Designation from the Food and Drug Administration (FDA) to treat IPF and PSC.
The company has three other drugs in its pipeline: PLN-1474, which is in a phase 2 trial to treat liver fibrosis associated with nonalcoholic steatohepatitis (NASH); PLN-101325, to treat muscular dystrophy; and PLN-101095, to treat solid tumors. The company said it had $555 million in cash as of June 30, enough to fund operations into the second half of 2026.
10 stocks we like better than Pliant Therapeutics
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Pliant Therapeutics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 25, 2023
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
